What happened
A cancer drug decades in the making significantly extended and improved the life of patients whose metastatic pancreatic cancer had stopped responding to previous treatments, researchers reported Sunday in The New England Journal of Medicine and at an American Society for Clinical Oncology meeting in Chicago. In a study of 500 last-stage pancreatic patients, those assigned Revolution Medicine’s daraxonrasib pill lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy. They also experienced fewer side effects.
Who said what
The “hotly anticipated” findings suggest researchers have “cracked one of the most stubbornly lethal cancers” by blocking mutated KRAS genes responsible for most pancreatic tumors, The Washington Post said. Daraxonrasib “ticks all of the boxes,” Dr. Rachna Shroff of the University of Arizona Cancer Center, who wasn’t involved in the study, told The Associated Press. “Having treated pancreatic cancer for 16 years, I actually started crying” at the results.
What next?
“Dozens of experimental drugs” targeting cancer-causing gene mutations are in development, stoking “optimism that this may be a turning point in the quest” for new treatment options, the AP said. Revolution Medicine is now testing daraxonrasib in earlier-stage cancer and in combination with other treatments.
Pill users lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy
